[1] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2022,7(9):851-861. [2] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease.Lancet,2021,397(10290):2212-2224. [3] Kanwal F, Shubrook JH, Younossi Z, et al. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring), 2021,29(9):1401-1412. [4] Ge X, Zheng L, Wang M, et al. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a populationbased observational study. BMJ Open,2020,10:e036663. [5] Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut,2021,70(7):1375-1382. [6] Younossi ZM, Golabi P, Paik JM, et al. Theglobal epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): asystematic review.Hepatology,2023,77(4):1335-1347. [7] Wang D, Xu Y, Zhu Z, et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019.Front Nutr,2022,9:1047129. [8] 秦莉,伍俊儒,刘雨晴,等.非酒精性脂肪肝病是心血管疾病危险因素.中国科学:生命科学,2024,54(11):2154-2166. [9] Paik JM, Kabbara K, Eberly KE, et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults.Hepatology. 2022,75(5):1204-1217. [10] Zusi C, Mantovani A, Olivieri F, et al. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.Dig Liver Dis, 2019,51(11):1586-1592. [11] 范建高,杨荣. 全球非酒精性脂肪性肝病的流行趋势与疾病负担. 中华消化杂志,2023,43(4):248-252. [12] Zusi C, Morandi A, Maguolo A, et al. Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children.Nutr Metab Cardiovasc Dis, 2021,31(5):1548-1555. [13] Zuo Q, Chen KL, Arredondo Eve A, et al. Pathwaypreferential estrogens prevent hepatosteatosis due to ovariectomy and high-fat diets.Nutrients,2021,13(10):3334. [14] 何方平. 我国非酒精性脂肪性肝病慢病管理实践现状和建议. 实用肝脏病杂志, 2023, 26(4): 460-462. [15] 郑慧慧, 王玉蓉, 宰国田. 非酒精性脂肪性肝病合并颈动脉粥样硬化斑块患者血清IL-17、IFN-γ和IL-6变化及其临床意义探讨. 实用肝脏病杂志, 2025, 28(1): 56-59. [16] 马敏, 许巧云. 非酒精性脂肪性肝病患者血清Arg-1水平和ApoB/ApoA1比值变化及其临床意义探讨. 实用肝脏病杂志, 2025, 28(1): 52-55. [17] Zuberbuhler F, Boursier J. Noninvasive diagnosis of liver fibrosis in NAFLD:tips tricks.Clin Res Hepatol Gastroenterol, 2019,43(6):658-662. [18] Zsombor Z, Rónaszéki AD, Csongrády B, et al. Evaluation ofartificial intelligence-calculated hepatorenal index for diagnosing mild and moderate hepatic steatosis in non-alcoholic fatty liver disease.Medicina (Kaunas), 2023,59(3):469. [19] Zou Y, Lan J, Zhong Y, et al. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study.Lipids Health Dis,2021,20(1):139. [20] Zou H, Zhao F, Lv X, et al. Development and validation of a new nomogram to screen for MAFLD.Lipids Health Dis, 2022,21(1):133. [21] Zou YY, Tang XB, Chen ZL, et al. Exercise intervention improves mitochondrial quality innon-alcoholic fatty liver disease zebrafish.Front Endocrinol (Lausanne), 2023,14:1162485. [22] Zhu W. Effective roles of exercise and diet adherence in non-alcoholic fatty liver disease.World J Gastroenterol, 2024,30(29):3456-3460. [23] Zhu JY, Chen M, Mu WJ, et al. Higd1a facilitates exercise-mediated alleviation of fatty liver in diet-induced obese mice. Metabolism, 2022,134:155241. [24] Zhu W, Sahar NE, Javaid HMA, et al. Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2.Cells, 2021,10(12):3306. |